MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Jin, Bo Xun ^a   Zhang, Yong Hong ^a   Jin, Wen Jing ^b   Sun, Xiang Ying ^b   Qiao, Gui Fang ^a   Wei, Ying Ying ^b   Sun, Li Bo ^a   Zhang, Wei Hong ^b   Li, Ning ^a  

^a Beijing QuantoBio Biotechnology Co Ltd Beijing Economic Technological Development Area ^*

^b Beijing Bio Ekon Biotechnology Share Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLINESTERASE; MICRORNA; PROTHROMBIN; SERUM ALBUMIN; VIRUS DNA;

ADULT; BLOOD; CASE CONTROL STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; BIOMARKERS; CASE-CONTROL STUDIES; CHOLINESTERASES; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; VIRAL LOAD;

EID: 84943744702     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15026     Document Type: Article

References (47)

1. Custer, B. et al. Global epidemiology of hepatitis B virus. Journal of clinical gastroenterology 38, S158-168 (2004).
2. Gitlin, N. Hepatitis B: diagnosis, prevention, and treatment. Clinical Chemistry 43, 1500-1506 (1997).
3. Valsamakis, A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clinical microbiology reviews 20, 426-439 (2007).
4. Zhu, C. L., Li, W. T., Li, Y., Gao, R. T. Serum levels of tissue inhibitor of metalloproteinase1 are correlated with liver fibrosis in patients with chronic hepatitis B. J Digest Dis 13, 558-563 (2012).
5. Schmeltzer, P. A., Talwalkar, J. A. Noninvasive tools to assess hepatic fibrosis: ready for prime time Gastroenterology clinics of North America 40, 507-521 (2011).
6. Ambros, V. The functions of animal microRNAs. Nature 431, 350-355 (2004).
7. Budhu, A. et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47, 897-907 (2008).
8. Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell metabolism 3, 87-98 (2006).
9. Bala, S. et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 56, 1946-1957 (2012).
10. Qi, P. et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PloS one 6, e28486 (2011).
11. Bolondi, L. et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48, 251-259 (2001).
12. Chen, Y. J. et al. Circulating microRNAs as a Fingerprint for Liver Cirrhosis. PloS one 8, e66577 (2013).
13. Bae, H. J. et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 33, 2557-2567 (2014).
14. Chen, Y. J. et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PloS one 8, e66577 (2013).
15. Drakaki, A., Hatziapostolou, M., Iliopoulos, D. Therapeutically targeting microRNAs in liver cancer. Curr Pharm Design 19, 1180-1191 (2013).
16. Estep, M. et al. Differential expression of miRNAs in the visceral adipose tissue of patients with nonalcoholic fatty liver disease. Aliment Pharm Therap 32, 487-497 (2010).
17. Kerle, V. et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 49, 3442-3449 (2013).
18. Li, L. M. et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70, 9798-9807 (2010).
19. Shi, C., Xu, X. MicroRNA-22 is down-regulated in hepatitis B virus-related hepatocellular carcinoma. Biomed Pharmacother 67, 375-380 (2013).
20. Xia, H., Lipj, O., Hui, K. M. MiR-214 targets-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One 7, e44206 (2012).
21. Zhou, J. et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29, 4781-4788 (2011).
22. Zhou, L. et al. MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int J Oncol 43, 661-669 (2013).
23. Zhu, K. et al. MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis 34, 2071-2079 (2013).
24. Chu, C. J., Hussain, M., Lok, A. S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 36:1408-1415.
25. Hepatology 36, 1408-1415 (2002).
26. Keshvari, M., Alavian, S. M., Sharafi, H. How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level Hepatitis Monthly 14, 110-110 (2014).
27. Gui, J. et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci 120, 183-193 (2011).
28. Brunetto, M. R. et al. A Serum MicroRNA Signature Is Associated with the Immune Control of Chronic Hepatitis B Virus Infection. Plos One 9, e110782-e110782 (2014).
29. Chen, Y. et al. A pilot study of serum microRNA signatures as a novel biomarker for occult hepatitis B virus infection. Medical Microbiology & Immunology 201, 389-395 (2012).
30. Zhang, Z. Q. et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagnostic Pathology 9, 135 doi: 10.1186/1746-1596-9-135 (2014).
31. Gel, T. et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. Journal of Medical Virology 83, 968-973 (2011).
32. Keeffe, E. B. et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 4, 936-962 (2006).
33. Gilad, S. et al. Serum MicroRNAs Are Promising Novel Biomarkers. PLoS one 3, e3148 (2008).
34. Boutz, D. R. et al. Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. The Journal of biological chemistry 286, 18066-18078 (2011).
35. Kumar, A. MicroRNA in HCV infection and liver cancer. Biochimica et biophysica acta 1809, 694-699 (2011).
36. Hu, J. et al. MiR-122 in hepatic function and liver diseases. Protein Cell 3, 364-371 (2012).
37. Henke, J. I. et al. microRNA-122 stimulates translation of hepatitis C virus RNA. European Molecular Biology Organization 27, 3300-3310 (2008).
38. Chang, J. et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA biology 1, 106-113 (2004).
39. Chen, Y. N. et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. Faseb J 25, 4511-4521 (2011).
40. Roderburg, C. et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53, 209-218 (2011).
41. Ura, S. et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49, 1098-1112 (2009).
42. Chen, Y. J. et al. Circulating microRNAs as a Fingerprint for Liver Cirrhosis. PloS one 21, e66577 (2013).
43. Bihrer, V. et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PloS one 6, e26971 (2011).
44. Xu, J. et al. Circulating MicroRNAs, miR21, miR122, and miR223, in patients with hepatocellular carcinoma or chronic hepatitis. Molecular carcinogenesis 50, 136-142 (2011).
45. McDaniel, K. et al. The functional role of microRNAs in alcoholic liver injury. Journal of cellular and molecular medicine 18, 197-207 (2014).
46. Singaravelu, R. et al. Hepatitis C virus induced upregulation of microRNA27: A novel mechanism for hepatic steatosis. Hepatology 59, 98-108 (2014).
47. Hu, J. et al. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. Transplantation 95, 991-999 (2013).